FAM70B as a Novel Prognostic Marker for Cancer Progression and Cancer-Specific Death in Muscle-Invasive Bladder Cancer.
10.4111/kju.2012.53.9.598
- Author:
Ho Won KANG
1
;
Hyung Yoon YOON
;
Yun Sok HA
;
Won Tae KIM
;
Yong June KIM
;
Seok Joong YUN
;
Sang Cheol LEE
;
Wun Jae KIM
Author Information
1. Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea. sjyun@chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
Bladder cancer;
Gene expression profiling;
Micro-array;
Prognosis
- MeSH:
Cohort Studies;
Cystectomy;
Disease-Free Survival;
Gene Expression;
Gene Expression Profiling;
Humans;
Kaplan-Meier Estimate;
Prognosis;
Real-Time Polymerase Chain Reaction;
RNA;
Urinary Bladder;
Urinary Bladder Neoplasms
- From:Korean Journal of Urology
2012;53(9):598-606
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To validate whether FAM70B, which was found in our micro-array profiling as a prognostic marker for cancer survival, could accurately predict prognosis in patients with muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: A total of 124 patients with MIBC were enrolled in this study. The FAM70B expression level was analyzed by real-time polymerase chain reaction by using RNA from tumor tissues. The prognostic effect of FAM70B was evaluated by Kaplan-Meier analysis and a multivariate Cox regression model. RESULTS: Kaplan-Meier estimates showed a significant difference in progression-free survival (log-rank test, p=0.011) and cancer-specific survival (log-rank test, p=0.017) according to FAM70B gene expression level. By multivariate Cox regression analysis, high FAM70B expression was predictive of cancer progression (hazard ratio [HR], 2.115, p=0.013) and cancer-specific death (HR, 1.925; p=0.033). In the subgroup analysis, high expression of FAM70B was associated with poor cancer-specific survival, progression-free survival, and overall survival in the patients who underwent cystectomy (log-rank test, p=0.013, p=0.036, p=0.005, respectively). In the chemotherapy group, FAM70B expression was associated with cancer-specific survival and progression-free survival (log-rank test, p=0.013, p=0.042, respectively). Moreover, high FAM70B expression was associated with shorter cancer-specific survival in localized or locally advanced tumor stages (log-rank test, p=0.016). CONCLUSIONS: We confirmed the significance of FAM70B as a prognostic marker in a validation cohort. Therefore, we propose that the FAM70B gene could be used to more precisely predict cancer progression and cancer-specific death in patients with MIBC.
